Nano-particle encapsulated doxorubicin as an anti-cancer chemotherapeutic agent: effect on the systemic immune response I

  • Lee, Hyun-Ah (The Cancer Center, Samsung Medical Center, Sunkyunkwan University) ;
  • Kim, Eui-Jin (School of Medicine, Div. Hematology/Oncology, Samsung Medical Center, Sunkyunkwan University) ;
  • Yu, Jeong-Jun (School of Medicine, Dept. Medical Engineering, Samsung Medical Center, Sunkyunkwan University) ;
  • Shu, Soo-Won (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
  • Ko, Young-Hyeh (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
  • Baek, So-Young (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
  • Park, Jin-Hee (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
  • Lee, Hong-Gi (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University)
  • Published : 2003.10.01

Abstract

The major hurdle of conventional chemotherapeutics is the toxicity to normal tissue. The possible therapeutic advantage(s) of nano-particle encapsulated chemotherapeutics (nano-molecules) may be the enhanced permeability and retention (EPR) effect. Nano-molecules with increase volume may incorporated into the tumor tissue selectively, which is composed of rather sparse structure. EPR effect may cause of increased effectiveness with lower tixicity to normal tissue of nano-chemotherapeutics. (omitted)

Keywords